Xtant Medical Holdings, Inc.: Form 10-Q for the period ended Jun 30, 2021
Filed with the SEC on Aug 5, 2021 and accepted by EDGAR at Aug 5, 2021, 07:31 ET.
Management's discussion and analysis
As filed, 22,838 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
This Management’s Discussion and Analysis provides material historical and prospective disclosures intended to enable investors and other users to assess our financial condition and results of operations. The following discussion should be read in conjunction with our condensed consolidated financial statements and accompanying notes included in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and accompanying notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed above in “Cautionary Statement Regarding Forward-Looking Statements” and elsewhere in this Form 10-Q.
Business Overview
We develop, manufacture and market regenerative medicine products and medical devices for domestic and international markets. Our products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease. We promote our products in the United States through independent distributors and stocking agents, supported by direct employees.
We have an extensive sales channel of independent commissioned agents and stocking distributors in the United States representing some or all of our products. We also maintain a national accounts program to enable our agents to gain access to integrated delivery network hospitals (“IDNs”) and through group purchasing organizations (“GPOs”). We have biologics contracts with major GPOs, as well as extensive access to IDNs across the United States for both biologics and spine hardware systems. While our focus is the United States market, we promote and sell our products internationally through stocking distribution partners in Canada, Mexico, South America, Australia, and certain Pacific region countries.
During 2021, we intend to focus primarily on four key growth initiatives: (1) introduce new products; (2) expand our distribution network; (3) penetrate adjacent markets; and (4) leverage our growth platform with technology and strategic acquisitions. Last year, we launched two new product lines, the Matriform Si and OsteoVive Plus, and this year, we have plans to release four new biologic products. We are also in the process this year of expanding our marketing programs and distribution network to increase the number of our distributors and help our distributors drive greater penetration in their markets. We intend to reinvest in our commercial team by bringing in new talent and then using this new talent and our existing and new products to leverage certain adjacent non-spine markets, such as the foot and ankle, cranio-maxilofacial, oncology, joint reconstruction and trauma markets. Finally, one of our key growth initiatives is to add depth to our product offering through targeted strategic acquisitions. While the intent of these four key growth initiatives is to increase our future revenues, no assurance can be provided that we will be successful in implementing these growth initiatives or increasing our future revenues.
Impact of the COVID-19 Pandemic
Since March 2020, the COVID-19 pandemic has caused business closures, severe travel restrictions and implementation of social distancing measures. Because of the COVID-19 pandemic, surgeons and their patients have been, and may continue to be, required, or are choosing, to defer procedures in which our products otherwise would be used, and many facilities that specialize in the procedures in which our products otherwise would be used have experienced temporary closures or reduced operating hours. The COVID-19 pandemic has also caused adverse effects on general commercial activity and the global economy. These factors have adversely affected, and may continue to adversely affect, our business and operations. Additionally, these factors have adversely affected, and may continue to adversely affect, our distributors, independent sales representatives, customers, contract manufacturers and suppliers.
While eased COVID-19 restrictions have caused our revenues to improve in the three and six months ended June 30, 2021, it is possible that these restrictions could be reinstated due to a resurgence of COVID-19 cases, which could once again have an adverse effect on our revenues. The full extent to which the COVID-19 pandemic will continue to impact our business will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 variants, the actions to contain it or treat its impact, and the availability and effectiveness of vaccines. We continue to monitor the impact of the COVID-19 pandemic on our business and operations.
See “Risk Factors” in Item 1A in our Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission for further information of the possible impact of the COVID-19 pandemic on our business.
Results of Operations
Comparison of Three and Six Months Ended June 30, 2021 and June 30, 2020
Revenue
Total revenue for the three and six months ended June 30, 2021 was $15.0 million and $27.5 million, respectively, which represents an increase of 42.2% and 8.7%, respectively, compared to $10.5 million and $25.3 million for the three and six months ended June 30, 2020, respectively. These revenue increases are largely attributed to the easing of restrictions associated with the COVID-19 pandemic in our key markets, which previously experienced a sudden drop in elective procedures beginning in early March 2020 as a result of the pandemic.
Cost of Sales and Gross Profit
Cost of sales consists primarily of manufacturing and product purchase costs as well as depreciation of surgical trays. Cost of sales also includes reserves for estimated excess inventory, inventory on consignment that may be missing and not returned, and reserves for estimated missing and damaged consigned surgical instruments. Cost of sales increased by 37.2%, or $1.5 million, to $5.5 million for the three months ended June 30, 2021 from $4.0 million for the three months ended June 30, 2020. Cost of sales increased by 8.4%, or $0.8 million, to $9.9 million for the six months ended June 30, 2021 from $9.1 million for the six months ended June 30, 2020. These increases in cost of sales are primarily due to higher revenue during the three and six months ended June 30, 2021 versus the comparable periods in 2020, as mentioned above.
Gross profit as a percentage of revenue increased to 63.5% for the three months ended June 30, 2021 compared to 62.2% for the same period in 2020. Gross profit as a percentage of revenue increased to 64.0% for the six months ended June 30, 2021 compared to 63.9% for the same period in 2020. These increases are primarily attributable to greater economies of scale.
General and Administrative
General and administrative expenses consist principally of personnel costs for corporate employees, cash-based and stock-based compensation related costs, legal, accounting and professional fees, and occupancy costs. General and administrative expenses increased 42.4%, or $1.2 million, to $4.2 million for the three months ended June 30, 2021, compared to $2.9 million for the same period in 2020. General and administrative expenses decreased 0.7%, or $0.1 million, to $7.2 million for the six months ended June 30, 2021, compared to $7.3 million for the same period in 2020. The increase for the three-month comparison is primarily attributable to additional legal settlement expenses of $0.6 million and additional stock-based compensation expense of $0.2 million during the three months ended June 30, 2021 coupled with $0.3 million less of expenses related to upgrades of our enterprise resource planning system during the three months ended June 30, 2020. The decrease for the six-month comparison is primarily attributable to reduced severance expenses of $0.7 million, partially offset by additional legal settlement expenses of $0.6 million during the six months ended June 30, 2021.
Sales and Marketing
Sales and marketing expenses consist primarily of sales commissions, personnel costs for sales and marketing employees, costs for trade shows, sales conventions and meetings, travel expenses, advertising, and other sales and marketing related costs. Sales and marketing expenses increased 43.5%, or $1.7 million, to $5.6 million for the three months ended June 30, 2021, compared to $3.9 million for the same period of 2020. Sales and marketing expenses increased 1.3%, or $0.1 million, to $10.4 million for the six months ended June 30, 2021, compared to $10.3 million for the same period of 2020. The increase for the three-month comparison is primarily due to additional sales commissions of $1.4 million due to higher revenues versus the comparable period in 2020. The increase for the six-month comparison is primarily due to additional sales commissions of $0.6 million due to higher revenues versus the comparable period in 2020, partially offset by reduced salaries and wages of $0.4 million.
Research and Development
Research and development expenses consist primarily of internal costs for the development of new technologies and processes. Research and development expenses increased 118.9%, or $0.1 million, to $0.2 million for the three months ended June 30, 2021, compared to $0.1 million for the three months ended June 30, 2020. Research and development expenses increased 29.7%, or $0.1 million, to $0.5 million for the six months ended June 30, 2021, compared to $0.4 million for the six months ended June 30, 2020. These increase in research and development expenses are associated with process improvement and product line extensions during the three and six months ended June 30, 2021 compared to the prior year periods.
Interest Expense
Interest expense consists of interest incurred from our debt instruments. Interest expense was $0.2 million for the three months ended June 30, 2021 compared to $2.1 million for the three months ended June 30, 2021. Interest expense was $0.2 million for the six months ended June 30, 2021 and $3.2 million for the six months ended June 30, 2020. The decrease in interest expense during the three and six months ended June 30, 2021 compared to the comparable periods in the prior year resulted from our October 1, 2020 debt restructuring which, among other things, reduced outstanding principal and paid-in-kind interest by $61.7 million.
Liquidity and Capital Resources
Working Capital
Since our inception, we have financed our operations through primarily operating cash flows, private placements of equity securities and convertible debt, debt facilities, common stock rights offerings, and other debt transactions. The following table summarizes our working capital as of June 30, 2021 and December 31, 2020 (in thousands):
| June 30, 2021 | December 31, 2020 | |
|---|---|---|
| Cash and cash equivalents | $20,312 | $2,341 |
| Accounts receivable, net | 6,985 | 6,880 |
| Inventories | 21,093 | 21,408 |
| Total current assets | 49,432 | 31,365 |
| Accounts payable | 2,639 | 2,947 |
| Accrued liabilities | 5,728 | 5,462 |
| Line of credit | 4,077 | — |
| Current portion of long-term debt | — | 16,797 |
| Total current liabilities | 12,915 | 25,649 |
| Total working capital | 36,517 | 5,716 |
Our increase in cash and cash equivalents is due primarily to the completion of a private placement of shares of common stock and warrants in February 2021. On February 24, 2021, we issued in a private placement to a single healthcare-focused institutional accredited investor 8,888,890 shares of our common stock at a purchase price of $2.25 per share, and a warrant to purchase up to 6,666,668 shares of our common stock. The warrant has an exercise price of $2.25 per share, subject to customary anti-dilution, but not price protection, adjustments, is immediately exercisable and expires on the five-year anniversary of the date of issuance. We received net proceeds of approximately $18.4 million, after deducting fees and other estimated offering expenses, from the private placement. We expect to use these net proceeds for working capital and other general corporate purposes.
Cash Flows
Net cash provided by operating activities for the first six months of 2021 was $0.9 million attributed primarily to the cash generated by our net loss of $0.8 million after adjusting for stock-based compensation of $0.9 million and depreciation and amortization of $0.7 million. For the comparable period of 2020, net cash used in operating activities was $1.6 million.
Net cash used in investing activities for the first six months of 2021 and 2020 was $1.0 million and $0.6 million, respectively, primarily representing purchases of property and equipment.
Net cash provided by financing activities was $18.2 million for the first six months of 2021, which was primarily attributable to $18.4 million of proceeds from our February 2021 private placement, net of issuance costs. Net cash used in financing activities was $0.1 million for the comparable period of 2020.
Current and Prior Credit Facilities
On May 6, 2021 (the “Closing Date”), the Company, as guarantor, and our subsidiaries, as borrowers (collectively, the “Borrowers”), entered into a (i) Credit, Security and Guaranty Agreement (Term Loan) (the “Term Credit Agreement”) with MidCap Financial Trust, in its capacity as agent (the “Agent”) and a lender and the additional lenders from time to time party thereto and (ii) Credit, Security and Guaranty Agreement (Revolving Loan) (the “Revolving Credit Agreement,” and, together with the Term Credit Agreement, the “Credit Agreements”), with the Agent and the lenders from time to time party thereto.
The Term Credit Agreement provides for a secured term loan facility (the “Term Facility”) in an aggregate principal amount of $12.0 million (the “Term Loan Commitment”), which was funded to the Borrowers on the Closing Date, and an additional $5.0 million tranche available solely at the discretion of the Agent and the lenders, for the purposes agreed to between the Company, the Borrowers and the lenders in advance of the making of loans under such additional tranche. The Revolving Credit Agreement provides for a secured revolving credit facility (the “Revolving Facility,” and, together with the Term Facility, the “Facilities”) under which the Borrowers may borrow up to $8.0 million (such amount, the “Revolving Loan Commitment”) at any one time, the availability of which is determined based on a borrowing base equal to percentages of certain accounts receivable and inventory of the Borrowers in accordance with a formula set forth in the Revolving Credit Agreement. All borrowings under the Revolving Facility are subject to the satisfaction of customary conditions, including the absence of default, the accuracy of representations and warranties in all material respects and the delivery of an updated borrowing base certificate.
The Facilities have a maturity date of May 1, 2026. Each of the Borrowers, and the Company, as guarantor, are jointly and severally liable for all of the obligations under the Facilities on the terms set forth in the Credit Agreements. The Borrowers’ obligations, and the Company’s obligations as a guarantor, under the Credit Agreements are secured by first-priority liens on substantially all of their assets, including, without limitation, all inventory, equipment, accounts, intellectual property and other assets of the Company and the Borrowers.
The proceeds of the Term Facility were used to pay transaction fees in connection with the Facilities and to pay in full all outstanding indebtedness and accrued interest under the Company’s prior credit facility, which is described below. The proceeds of the Revolving Facility may be used to pay transaction fees in connection with the Facilities, to pay in full all outstanding indebtedness and accrued interest under the Company’s prior credit facility, and for working capital and general corporate purposes.
The loans and other obligations pursuant to the Credit Agreements bear interest at a per annum rate equal to the sum of the LIBOR rate, as such term is defined in the Credit Agreements, plus the applicable margin of 7.00% in the case of the Term Credit Agreement, and 4.50% in the case of the Revolving Credit Agreement, subject in each case to a LIBOR floor of 1.00%.
The Credit Agreements contain affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants that, among other things, limit or restrict the ability of the Borrowers, subject to negotiated exceptions, to incur additional indebtedness and additional liens on their assets, engage in mergers or acquisitions or dispose of assets, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments, and change the nature of their businesses. In addition, the Credit Agreements require the Borrowers and the Company to maintain net product revenue at or above minimum levels and to maintain a minimum adjusted EBITDA and a minimum liquidity, in each case at levels specified in the Credit Agreements. As of June 30, 2021, we were in compliance with all covenants under the Credit Agreements.
On May 6, 2021, contemporaneously with the execution and delivery of the Credit Agreements, that certain Second Amended and Restated Credit Agreement, dated March 29, 2019, among the Company, the Borrowers, OrbiMed Royalty Opportunities II, LP (“Royalty Opportunities”) and ROS Acquisition Offshore LP, as subsequently amended (the “Second A&R Credit Agreement”), which was scheduled to mature on December 31, 2021, was terminated in accordance with the terms thereof and all outstanding amounts were repaid by the Borrowers to Royalty Opportunities in its role as sole lender thereunder.
Cash Requirements
We believe that our $20.5 million of cash and cash equivalents as of June 30, 2021, together with amounts available under the Facilities, will be sufficient to meet our anticipated cash requirements through at least August 2022. However, we may require or seek additional capital to fund our future operations and business strategy prior to August 2022. Accordingly, there is no assurance that we will not need or seek additional financing prior to such time.
We may elect to raise additional financing even before we need it if market conditions for raising additional capital are favorable. We may seek to raise additional financing through various sources, such as equity and debt financings, additional debt restructurings or refinancings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This is particularly true if economic and market conditions deteriorate.
To the extent that we raise additional capital through the sale of equity or convertible debt securities or the restructuring or refinancing of our debt, the interests of our current stockholders may be diluted, and the terms may include discounted equity purchase prices, warrant coverage, liquidation or other preferences that would adversely affect the rights of our current stockholders. If we issue common stock, we may do so at purchase prices that represent a discount to our trading price and/or we may issue warrants to the purchasers, which could dilute our current stockholders. If we issue preferred stock, it could adversely affect the rights of our stockholders or reduce the value of our common stock. In particular, specific rights granted to future holders of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. Additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Prior to raising additional equity or debt financing, we may be required to obtain the consent of the Agent under our Credit Agreements and/or ROS Acquisition Offshore LP (“ROS”) and Royalty Opportunities under our Investor Rights Agreement with them, and no assurance can be provided that they would provide such consent, which could limit our ability to raise additional financing and the terms thereof.
Off Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity or capital expenditures, or capital resources that are material to an investor in our common stock.
Critical Accounting Estimates
Management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses, and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions, and any such differences may be material.
There have been no changes in our critical accounting estimates for the three and six months ended June 30, 2021 as compared to the critical accounting estimates described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
Controls and procedures
As filed, 1,429 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act as of June 30, 2021. Based upon that evaluation, our principal executive officer and principal financial officer concluded that as of June 30, 2021, our disclosure controls and procedures were effective.
Changes in Internal Control over Financial Reporting
There were no changes in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended June 30, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-04-01 to 2021-06-30 | $15.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2021-01-01 to 2021-06-30 | $27.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2021-04-01 to 2021-06-30 | $5.5m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2021-01-01 to 2021-06-30 | $9.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2021-04-01 to 2021-06-30 | $9.5m | us-gaap:GrossProfit |
| Gross profit | 6 months2021-01-01 to 2021-06-30 | $17.6m | us-gaap:GrossProfit |
| Research and development | 3 months2021-04-01 to 2021-06-30 | $243.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2021-01-01 to 2021-06-30 | $458.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-04-01 to 2021-06-30 | −$491.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-01 to 2021-06-30 | −$497.0k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-04-01 to 2021-06-30 | $199.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2021-01-01 to 2021-06-30 | $201.0k | us-gaap:InterestExpense |
| Income tax | 3 months2021-04-01 to 2021-06-30 | $43.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2021-01-01 to 2021-06-30 | $64.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-04-01 to 2021-06-30 | −$733.0k | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-06-30 | −$762.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-04-01 to 2021-06-30 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2021-01-01 to 2021-06-30 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-04-01 to 2021-06-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2021-01-01 to 2021-06-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-04-01 to 2021-06-30 | 86,707,286 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2021-01-01 to 2021-06-30 | 83,993,159 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2021-01-01 to 2021-06-30 | $942.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2021-01-01 to 2021-06-30 | $1.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-06-30 | $20.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-06-30 | $49.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-06-30 | $59.7m | us-gaap:Assets |
| Current liabilities | At period end2021-06-30 | $12.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-06-30 | $25.8m | us-gaap:Liabilities |
| Long-term debt | At period end2021-06-30 | $11.7m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2021-06-30 | $33.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-21-018670. Last ingested by Listed: Oct 24, 2026, 15:08 ET. Listed shows no prices and gives no investment advice.